Literature DB >> 9672434

Management of withdrawal syndromes and relapse prevention in drug and alcohol dependence.

N S Miller1, M S Gold.   

Abstract

The primary care physician is in a good position to diagnose, manage and intervene with patients who are undergoing the process of treatment and recovery from alcohol and drug disorders. Medications such as benzodiazepines are effective in the treatment of withdrawal syndromes, and naltrexone and disulfiram can be used to augment relapse prevention. Patients may also participate in psychosocial methods of addiction treatment that can reduce the risk of relapse and improve their psychosocial, health, legal and employment status.

Entities:  

Mesh：

Year:  1998        PMID： 9672434

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN： 0002-838X            Impact factor:   3.292


  14 in total

Review 1.  Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors.

Authors:  Jing Liang; Richard W Olsen
Journal:  Acta Pharmacol Sin       Date:  2014-08       Impact factor: 6.150

2.  Treatment of Alcohol Withdrawal Syndrome with and without Dexmedetomidine.

Authors:  Muna Beg; Sara Fisher; Dana Siu; Sudhir Rajan; Lawrence Troxell; Vincent X Liu
Journal:  Perm J       Date:  2016

Review 3.  Metabolic diversity as a reason for unsuccessful detoxification from benzodiazepines: the rationale for serum BZD concentration monitoring.

Authors:  Anna Basińska-Szafrańska
Journal:  Eur J Clin Pharmacol       Date:  2021-01-03       Impact factor: 2.953

Review 4.  The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.

Authors:  Kelly E Dunn; Stacey C Sigmon; Eric C Strain; Sarah H Heil; Stephen T Higgins
Journal:  Drug Alcohol Depend       Date:  2011-07-08       Impact factor: 4.492

5.  Histone deacetylases mediate GABAA receptor expression, physiology, and behavioral maladaptations in rat models of alcohol dependence.

Authors:  John Peyton Bohnsack; Benjamin A Hughes; Todd K O'Buckley; Kamyra Edokpolor; Joyce Besheer; A Leslie Morrow
Journal:  Neuropsychopharmacology       Date:  2018-02-27       Impact factor: 7.853

Review 6.  [Diagnosis, differential diagnosis and therapy of substance use disorders in general hospital (general section)].

Authors:  Anton Schmick; Josef Jenewein; Sönke Böttger
Journal:  Neuropsychiatr       Date:  2018-01-11

Review 7.  Alcohol Withdrawal Syndrome: Benzodiazepines and Beyond.

Authors:  Ankur Sachdeva; Mona Choudhary; Mina Chandra
Journal:  J Clin Diagn Res       Date:  2015-09-01

8.  Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS).

Authors:  Kenneth Blum; Marlene Oscar-Berman; Zsolt Demetrovics; Debmalya Barh; Mark S Gold
Journal:  Mol Neurobiol       Date:  2014-05-31       Impact factor: 5.590

9.  Effect of variations in treatment regimen and liver cirrhosis on exposure to benzodiazepines during treatment of alcohol withdrawal syndrome.

Authors:  Pavel Gershkovich; Kishor M Wasan; Charles Ribeyre; Fady Ibrahim; John H McNeill
Journal:  Drugs Context       Date:  2015-08-07

Review 10.  Clinical management of alcohol withdrawal: A systematic review.

Authors:  Shivanand Kattimani; Balaji Bharadwaj
Journal:  Ind Psychiatry J       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.